Details for New Drug Application (NDA): 210737
✉ Email this page to a colleague
NDA 210737 describes REDITREX, which is a drug marketed by Nordic Grp and is included in one NDA. Additional details are available on the REDITREX profile page.
The generic ingredient in REDITREX is methotrexate. There are twenty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
The generic ingredient in REDITREX is methotrexate. There are twenty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
Summary for 210737
| Tradename: | REDITREX |
| Applicant: | Nordic Grp |
| Ingredient: | methotrexate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210737
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 7.5MG/0.3ML (7.5MG/0.3ML) | ||||
| Approval Date: | Nov 27, 2019 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 10MG/0.4ML (10MG/0.4ML) | ||||
| Approval Date: | Nov 27, 2019 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 12.5MG/0.5ML (12.5MG/0.5ML) | ||||
| Approval Date: | Nov 27, 2019 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
